Press Releases

Memorial Medical Care, PC, a practice of Memorial Sloan Kettering Cancer Center physicians, in collaboration with New York Cancer & Blood Specialists (NYCBS), recently announced the opening of a new comprehensive cancer care practice in the Flatbush section of Brooklyn.

Jeffrey Zwicker, MD, has been named Chief of the Hematology Service at Memorial Sloan Kettering Cancer Center (MSK). He joins MSK from Harvard University Medical School, where he was an Associate Professor of Medicine, and Beth Israel Deaconess Medical Center (BIDMC), where he served as Chief of Benign Hematology in the Division of Hematology since 2017. Dr. Zwicker succeeds MSK’s Interim Hematology Service Chief, Marcel van den Brink, MD, PhD.

Memorial Sloan Kettering Cancer Center announced it has selected Epic to provide a new platform for integrated care that will ensure patients and physicians can more easily access electronic health records.

Memorial Sloan Kettering Cancer Center (MSK) today announced the appointment of Lawrence Schwartz, MD, as MSK’s new Chair of the Department of Radiology. He will assume the role in early 2023. Dr. Schwartz is internationally recognized for his expertise in quantitative imaging, artificial intelligence in cancer imaging, and for his pioneering work in the development and validation of novel imaging biomarkers in oncology.

Memorial Sloan Kettering Cancer Center (MSK) is proud to announce that it is ranked among the top 15 organizations with the greatest number of highly cited scientific researchers worldwide, according to the annual list of Highly Cited Researchers published by the Institute for Scientific Information at Clarivate.

Fred’s Team, MSK’s running program, has made history by surpassing $100 million in total funds raised for cancer research.

Memorial Sloan Kettering Cancer Center (MSK) announced today that the U.S. Food and Drug Administration (FDA) has approved the oral MEK inhibitor drug cobimetinib (COTELLIC®) for the treatment of adult patients with the family of blood diseases know as histiocytic neoplasms (HN). These diseases include: Erdheim-Chester Disease, Rosai-Dorfman, and Langerhans Histiocytosis. Cobimetinib is an oral inhibitor of MEK1 and MEK2 currently approved to treat melanoma.

Carol Morris, MD, MS, has assumed the position of Chief of the Orthopaedic Surgery Service at Memorial Sloan Kettering Cancer Center (MSK).